Flynn McGuire at the University of Utah, for example, said: The amount of hype to evidence is so skewed, its crazy, and that BPC-157 Should not be used by humans. At the same time, other physicians and researchers see things differently, and are prescribing BPC-157 for a wide variety of illnesses and injuries: ulcerative colitis, orthopedic injuries, and even mental health
For instance, TB-500 sulfoxide, which is produced by monocytes when exposed to glucocorticoids, has been shown to inhibit neutrophil chemotaxis and possess strong anti-inflammatory properties [8]
The 30 mL estimate came from animal studies and is framed around intravenous dosing, so read it as a guardrail rather than a hard limit
Its important to be clear: No clinical trials in menopausal women exist
[DOI] [PubMed] [Google Scholar] 111.Shi H, Dirienzo D, Zemel MB
Why the off phase matters: continuous dosing flattens pituitary response over time